So if I understand you correctly, a "correction" is effectively a reversion of the vascular dementia status of the patient?  Is that right, DebKCardsPA?

If so, that would be a huge win for us.  Biogen's market cap went up by several billion dollars when their drug showed a "slowdown" in Alzheimer's.  I don't think there is any drug out there that has shown any such "correction" (if I am reading you right).